** Shares of gene therapy company MeiraGTx Holdings plc MGTX.O up 13.6% at $7.76 premarket
** Co says early-stage study data for its experimental gene therapy, rAAV8.hRKp.AIPL1, showed safety, efficacy and meaningful responses for treatment of genetic eye condition called retinal dystrophy
** Says children who were blind at birth were treated with the gene therapy and showed visual acuity in eyes after four or more weeks in small study
** The therapy showed improved functional vision and evidence of protection against progressive retinal degeneration, without serious adverse effects
** Retinal dystrophy is caused due to genetic deficiency of type of protein called AIPL1, which leads severe impairment of sight from birth
** Co says study data is published in medical journal The Lancet
** MGTX stock has risen ~16% in last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。